Adjuvant Pembrolizumab and Survival in Renal-Cell Carcinoma | NEJM
Автор: NEJM Group
Загружено: 2024-04-18
Просмотров: 2436
Описание:
Adjuvant pembrolizumab was approved for patients with renal-cell carcinoma on the basis of improvements in disease-free survival observed in the KEYNOTE-564 trial. Data on overall survival are needed.
Research findings are summarized in a Quick Take video.
To see the full article, follow this link: https://nej.md/3TVLuKz
#oncology #cancerresearch #clinicaltrials #medicalresearch #nejm
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: